It suggests that CAR-T cell therapy combined with suppression of AIM2 and α1-AR may induce antitumor effects and alleviate the toxic side effects of CAR-T cells, such as CRS [427]. The gene discussed is AIM2; the disease is congenital rubella syndrome.